secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2026-05-18T10:47:00+00:00
Accession:  0001628280-26-035793
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Context Therapeutics buys out future milestones and royalties for CT-202 from BioAtla for $6.5M total
--------------------------------------------------------------------------------

- Paid $4.5M upfront and $2M due by Aug 1, 2026 to eliminate all future milestone/royalty obligations.
- License becomes irrevocable, royalty-free, fully paid-up, and non-terminable.
- BioAtla no longer entitled to future milestones or royalties for CT-202.
- Phase 1 trial initiation for CT-202 expected in Q3 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000162828026035793/0001628280-26-035793-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000162828026035793/cntx-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-035793

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer